Linezolid treatment for gram-positive infections: a retrospective comparison with teicoplanin. - Test2 - elhamkhani - TriplyDB

Linezolid treatment for gram-positive infections: a retrospective comparison with teicoplanin.

Linezolid treatment for gram-positive infections: a retrospective comparison with teicoplanin.

http://www.wikidata.org/entity/Q34989916

about

Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA MRSA: treating people with infection.

P2860

Q22305769-480DABFD-699F-44E4-8224-63833C4887F8 Q33850476-B7432A95-C834-44D3-BD1B-1B4537E72F50

P2860

Linezolid treatment for gram-positive infections: a retrospective comparison with teicoplanin.

http://www.wikidata.org/entity/Q34989916

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Linezolid treatment for gram-p ...... e comparison with teicoplanin.

@ast

Linezolid treatment for gram-p ...... e comparison with teicoplanin.

@en

Linezolid treatment for gram-p ...... e comparison with teicoplanin.

@nl

type

label

Linezolid treatment for gram-p ...... e comparison with teicoplanin.

@ast

Linezolid treatment for gram-p ...... e comparison with teicoplanin.

@en

Linezolid treatment for gram-p ...... e comparison with teicoplanin.

@nl

prefLabel

Linezolid treatment for gram-p ...... e comparison with teicoplanin.

@ast

Linezolid treatment for gram-p ...... e comparison with teicoplanin.

@en

Linezolid treatment for gram-p ...... e comparison with teicoplanin.

@nl

P1433

Q34989916-D569B97C-7893-479A-9197-8260D87D80AE

P1476

Q34989916-9D7CD932-1514-4FD3-A2E6-501A54710A2E

P2093

Q34989916-005CD903-6B16-498F-8F65-942D6F41C637

Q34989916-0669427D-756A-401A-AA10-5737CD9FA0B5

Q34989916-12CB4E96-2E79-44A7-B43F-F4BCD8C08186

Q34989916-35B15D37-981D-42CB-B3E7-5996F3DB508F

Q34989916-38CF674C-1F44-4AE0-AA86-F916E690B516

Q34989916-4B10D3EB-8737-4DE6-9328-8DAA29BA3718

Q34989916-6D8105EC-575D-4361-98BB-36C1E25C3ED7

Q34989916-6E1D43F5-52B3-4460-8D76-D23F5C45FF1E

Q34989916-7D8DF5D7-4C20-4E68-B880-27A3C328DC3E

Q34989916-814CDE00-5023-49A3-AA91-54360E634B14

P2860

Q34989916-338AFE3A-5A77-4A93-8586-725451066BFB

Q34989916-35B44820-D455-4F4A-93A7-216930D36E4B

Q34989916-38D63134-C8D3-493D-8F1F-7D25E9E34497

Q34989916-508FB0FD-BB5C-4D87-A62D-0671D13302ED

Q34989916-666547CC-F30D-4BC9-B431-D0A649EB3BD9

Q34989916-69F19FEF-2F42-4058-94E6-934AC51C564D

Q34989916-768D7F89-AFFD-4932-A9A3-E9C17DE56C2E

Q34989916-77C3F202-54F4-4B33-8033-46FFCA5599C7

Q34989916-D43386E6-7AFE-4F18-B8E6-F19DEF72FBA4

Q34989916-FBE88220-D8DE-4554-B1D1-CF568F36F6AC

P304

Q34989916-D3A08ABA-8347-43AD-8C52-B6124D65E955

P31

Q34989916-3749873B-08F3-44E5-A175-A3EE7991CA98

P356

Q34989916-F8780304-3B17-487A-8EFB-671045E71353

P433

Q34989916-657F3A8A-8A10-4A70-86D1-C1114ECA35D6

P478

Q34989916-6CFD0CC4-4FD6-4A7A-A24E-7B041BA21236

P577

Q34989916-39A9D423-64E2-4561-A193-05681C1A1F0F

P698

Q34989916-80FC5912-2171-4261-AB64-D510D14F3E00

P921

Q34989916-812A24AB-FCD6-4AFE-B078-33E4A6DC6D8C

P356

JOC.2009.21.3.311

P1433

Journal of Chemotherapy

P1476

Linezolid treatment for gram-p ...... e comparison with teicoplanin.

@en

P2093

Biancofiore G

http://www.w3.org/2001/XMLSchema#string

Dal Canto L

http://www.w3.org/2001/XMLSchema#string

Didoni G

http://www.w3.org/2001/XMLSchema#string

Doria R

http://www.w3.org/2001/XMLSchema#string

Filipponi F

http://www.w3.org/2001/XMLSchema#string

Furneri G

http://www.w3.org/2001/XMLSchema#string

Gemignani G

http://www.w3.org/2001/XMLSchema#string

Malacarne P

http://www.w3.org/2001/XMLSchema#string

Menichetti F

http://www.w3.org/2001/XMLSchema#string

Mosca C

http://www.w3.org/2001/XMLSchema#string

P2860

A review of linezolid: the first oxazolidinone antibiotic.

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials.

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

Linezolid: the first oxazolidinone antimicrobial.

Quinupristin-dalfopristin and linezolid: evidence and opinion.

Healthcare-associated pneumonia in adults: management principles to improve outcomes.

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.

Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.

An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects.

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.

P304

311-316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/JOC.2009.21.3.311

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19567352

http://www.w3.org/2001/XMLSchema#string

P921

Gram-positive bacteria